

Estonia

Population 2015

1.3 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.025 (0.025–0.025)	1.9 (1.9–1.9)
Mortality (HIV+TB only)	<0.01 (<0.01–0.015)	0.25 (0–1.2)
Incidence (includes HIV+TB)	0.24 (0.2–0.27)	18 (15–21)
Incidence (HIV+TB only)	0.024 (0.021–0.028)	1.8 (1.6–2.1)
Incidence (MDR/RR-TB)**	0.071 (0.05–0.092)	5.4 (3.8–7)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0-14 years	> 14 years	Total
Females	0.016 (0.014–0.018)	0.051 (0.023–0.079)	0.067 (0.038–0.097)
Males	0 (0–0)	0.17 (0.13–0.2)	0.17 (0.13–0.2)
Total	0.016 (0.013–0.02)	0.22 (0.2–0.24)	0.24 (0.2–0.27)

TB case notifications, 2015	
Total cases notified	217
Total new and relapse	206
- % tested with rapid diagnostics at time of diagnosis	73%
- % with known HIV status	96%
- % pulmonary	91%
- % bacteriologically confirmed among pulmonary	87%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	87% (76–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.12 (0.09–0.16)

TB/HIV care in new and relapse TB patients, 2015		
	Number	(%)
Patients with known HIV-status who are HIV-positive	23	12%
- on antiretroviral therapy	21	91%

Drug-resistant TB care, 2015			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			47 (36–59)
Estimated % of TB cases with MDR/RR-TB	16% (10–23)	54% (37–71)	
% notified tested for rifampicin resistance	84%	87%	184
MDR/RR-TB cases tested for resistance to second-line drugs			37
Laboratory-confirmed cases		MDR/RR-TB: 43, XDR-TB: 9	
Patients started on treatment ****		MDR/RR-TB: 34, XDR-TB: 9	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2014	84%	194
Previously treated cases, excluding relapse, registered in 2014	100%	1
HIV-positive TB cases, all types, registered in 2014	71%	14
MDR/RR-TB cases started on second-line treatment in 2013	70%	44
XDR-TB cases started on second-line treatment in 2013	40%	10

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016	
National TB budget (US\$ millions)	<1
Funding source: 100% domestic, international, <1% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015




Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded
— Funded internationally
— Funded domestically